1. Home
  2. MBIO vs CDIO Comparison

MBIO vs CDIO Comparison

Compare MBIO & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.71

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

HOLD

Current Price

$1.94

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBIO
CDIO
Founded
2015
2017
Country
United States
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
5.1M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MBIO
CDIO
Price
$0.71
$1.94
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
30.0K
529.6K
Earning Date
03-19-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
98.99
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$171,906.75
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.18
52 Week High
$7.00
$7.91

Technical Indicators

Market Signals
Indicator
MBIO
CDIO
Relative Strength Index (RSI) 28.85 36.00
Support Level $0.53 $1.64
Resistance Level $1.00 $2.03
Average True Range (ATR) 0.06 0.47
MACD -0.02 -0.26
Stochastic Oscillator 9.18 1.81

Price Performance

Historical Comparison
MBIO
CDIO

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Share on Social Networks: